Circulating miR34a levels as a potential biomarker in the follow-up of Ewing sarcoma

• DOI: 10.1007/s12079-020-00567-2
• Publication Date: 2020-06-05T16:03:50Z
• Authors: Marika Sciandra; Alessandra De Feo; Alessandro Parra; Lorena Landuzzi; Pier-Luigi Lollini; Maria Cristina Ma...; Gianfranco Mattia; Giada Pontecorvi; Cristina Baricordi; Clara Guerzoni; Alberto Bazzocchi; Alessandra Longhi; Katia Scotlandi
• Keywords: Circulating biomarkers; Ewing sarcoma; Metastases; miR34a; miRNAs; 03 medical and health sciences; 0302 clinical medicine; circulating biomarkers; Ewing sarcoma; metastases; miR34a; miRNAs; 3. Good health

Appropriate tools for monitoring sarcoma progression are still limited. The aim of the present study was to investigate the value of miR-34a-5p (miR34a) as a circulating biomarker to follow disease progression and measure the therapeutic response. Stable forced re-expression of miR34a in Ewing sarcoma (EWS) cells significantly limited tumor growth in mice. Absolute quantification of miR34a in the plasma of mice and 31 patients showed that high levels of this miRNA inversely correlated with tumor volume. In addition, miR34a expression was higher in the blood of localized EWS patients than in the blood of metastatic EWS patients. In 12 patients, we followed miR34a expression during preoperative chemotherapy. While there was no variation in the blood miR34a levels in metastatic patients at the time of diagnosis or after the last cycle of preoperative chemotherapy, there was an increase in the circulating miR34a levels in patients with localized tumors. The three patients with the highest fold-increase in the miR levels did not show evidence of metastasis. Although this analysis should be extended to a larger cohort of patients, these findings imply that detection of the miR34a levels in the blood of EWS patients may assist with the clinical management of EWS.